Indian pharma giant Lupin's shares surged more than 2 per cent to touch the all time high level after the company declared that it had added Huminsulin in India to its diabetes portfolio by purchasing it from Eli Lilly and Co.

Lupin Ltd. acquires Huminsulin range from Eli Lilly, strengthening its position in the Indian diabetes market.

The Huminsulin range is vital for managing both type 1 and type 2 diabetes, helping control blood sugar levels in adults and children

Lupin has been marketing the 'Huminsulin' range of products through existing distribution and promotion agreements with Eli Lilly and Company (Lilly), India, Lupin said in a regulatory filing.

Lupin acquires Huminsulin from Eli Lilly to strengthen diabetes portfolio in India, offering affordable healthcare options.

The stock of the pharmaceutical company, Lupin is quoting higher for the sixth straight trading day; it has rallied 10 per cent during the period

Mumbai: Global pharma major Lupin Limited has announced the acquisition of Huminsulin in India from Eli Lilly and Company to further enhance its diabetes portfolio. Lupin has been marketing

Lupin strengthens its diabetes portfolio with the acquisition of Huminsulin products from Eli Lilly, including Insulin Human formulations, widely used for managing type 1 and type 2 diabetes mellitus

There is a significant Indian population affected with diabetes for both Type 1 and Type 2 Diabetes Mellitus, where Insulin Human is prescribed for management along with other concomitant therapies, the company stated.